Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

NCT04182724 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
57
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Chinese PLA General Hospital